Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Gemcitabine in Relapsed Mantle Cell Lymphoma
NCT00377052Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, gemcitabine in mantle cell lymphoma (MCL), sponsored by Canadian Cancer Trials Group. Started Jan 2007; status: completed.
02
Drugs
bortezomibgemcitabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00377052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00377052.